Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jiang Long

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0010-5067; OpenAlex author ID A5018181452. Sources: OpenAlex.

Their work

Papers
50 (first author 5, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2011: 2 papers · 2012: 5 papers · 2013: 4 papers · 2014: 7 papers · 2015: 8 papers · 2016: 6 papers · 2017: 6 papers · 2018: 4 papers · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers

Papers 50

  1. Early Diagnosis and Prognosis Prediction of Pancreatic Cancer Using Engineered Hybrid Core-Shells in Laser Desorption/Ionization Mass Spectrometry. Co-author DOI 10.1002/adma.202311431↗
  2. Codetection of Proteins and RNAs on Extracellular Vesicles for Pancreatic Cancer Early Diagnosis. First author DOI 10.1021/acs.analchem.3c05858↗
  3. The Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation. Co-author DOI 10.1158/2326-6066.cir-23-0205↗
  4. Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips. Last author DOI 10.1016/j.isci.2022.105723↗
  5. Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma. Last author DOI 10.21037/atm-22-407↗
  6. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗
  7. Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer. Co-author DOI 10.2147/cmar.s202543↗
  8. Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment. Co-author DOI 10.3791/59507↗
  9. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2018.05.479↗
  10. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  11. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  12. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001073↗
  13. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Co-author DOI 10.1016/j.canlet.2016.10.046↗
  14. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2016.08.005↗
  15. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000001741↗
  16. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5579-3↗
  17. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
  18. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Co-author DOI 10.3892/ol.2016.5501↗
  19. New insights into perineural invasion of pancreatic cancer: More than pain. Co-author DOI 10.1016/j.bbcan.2016.01.002↗
  20. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Co-author DOI 10.1016/j.pan.2016.09.007↗
  21. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Co-author DOI 10.1016/j.pan.2016.09.013↗
  22. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/m… Co-author DOI 10.1038/srep19222↗
  23. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Co-author DOI 10.18632/oncotarget.6819↗
  24. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. Co-author DOI 10.3390/ijms17071090↗
  25. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  26. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Co-author DOI 10.1016/j.bbcan.2014.11.004↗
  27. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Co-author DOI 10.1016/j.canlet.2015.01.023↗
  28. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.02.014↗
  29. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.03.012↗
  30. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Co-author DOI 10.1038/cr.2015.30↗
  31. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. Co-author DOI 10.1186/s13014-014-0312-5↗
  32. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Co-author DOI 10.1245/s10434-014-4021-y↗
  33. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Co-author DOI 10.1007/s00259-014-2688-8↗
  34. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Co-author DOI 10.1016/j.canlet.2014.01.004↗
  35. LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process. Co-author DOI 10.1016/j.canlet.2014.02.013↗
  36. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. Co-author DOI 10.1016/j.pan.2014.05.797↗
  37. Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. Co-author DOI 10.1016/s1499-3872(14)60264-2↗
  38. Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Co-author DOI 10.1155/2014/925845↗
  39. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis. Co-author DOI 10.1186/1476-4598-13-187↗
  40. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. Co-author DOI 10.1007/s11605-013-2389-9↗
  41. Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic canc… Co-author DOI 10.1371/journal.pone.0071189↗
  42. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. First author DOI 10.3892/ijo.2013.1780↗
  43. Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. Co-author DOI 10.3892/ijo.2013.1901↗
  44. Stroma and pancreatic ductal adenocarcinoma: an interaction loop. First author DOI 10.1016/j.bbcan.2012.04.002↗
  45. Combinational therapy: new hope for pancreatic cancer? Co-author DOI 10.1016/j.canlet.2011.11.029↗
  46. Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. First author DOI 10.1111/j.1582-4934.2011.01478.x↗
  47. microRNA signature for human pancreatic cancer invasion and metastasis. Co-author DOI 10.3892/etm.2012.585↗
  48. Development of a unique mouse model for pancreatic cancer lymphatic metastasis. Co-author DOI 10.3892/ijo.2012.1613↗
  49. Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. First author DOI 10.1159/000334465↗
  50. Overcoming drug resistance in pancreatic cancer. Co-author DOI 10.1517/14728222.2011.566216↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 41 shared papers, 2011–2020 · strength 1.97
  2. Jin Xu · 37 shared papers, 2011–2018 · strength 1.72
  3. Chen Liu · 35 shared papers, 2011–2018 · strength 1.66
  4. Liang Liu · 29 shared papers, 2013–2020 · strength 1.43
  5. Quanxing Ni · 23 shared papers, 2012–2018 · strength 1.18
  6. Guopei Luo · 20 shared papers, 2011–2018 · strength 0.97
  7. Meng Guo · 12 shared papers, 2014–2018 · strength 0.69
  8. Kaizhou Jin · 11 shared papers, 2015–2018 · strength 0.65
  9. Chuntao Wu · 11 shared papers, 2013–2020 · strength 0.60
  10. Huaxiang Xu · 10 shared papers, 2013–2020 · strength 0.55
  11. He Cheng · 9 shared papers, 2015–2018 · strength 0.54
  12. Zuqiang Liu · 10 shared papers, 2013–2017 · strength 0.50
  13. Beiyuan Hu · 3 shared papers, 2022–2024 · strength 0.47
  14. Si Shi · 10 shared papers, 2012–2017 · strength 0.41
  15. Zhiwen Xiao · 8 shared papers, 2012–2017 · strength 0.36
  16. Yi Qin · 8 shared papers, 2013–2017 · strength 0.34
  17. Qiongzhu Dong · 2 shared papers, 2022–2024 · strength 0.32
  18. Wen-Quan Wang · 6 shared papers, 2013–2018 · strength 0.31
  19. Jiuliang Yan · 2 shared papers, 2022–2023 · strength 0.30
  20. Chuntao Wu · 2 shared papers, 2022–2023 · strength 0.30
  21. Haitao Gu · 2 shared papers, 2022–2023 · strength 0.30
  22. Shunrong Ji · 7 shared papers, 2013–2017 · strength 0.29
  23. Wenyan Xu · 6 shared papers, 2014–2017 · strength 0.26
  24. Wenquan Wang · 4 shared papers, 2015–2020 · strength 0.25
  25. Xu Wang · 2 shared papers, 2019–2023 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.